By Fineline Cube 
China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix’s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.
Partnership and Technology
Under the agreement, Delonix will leverage WuXi Vaccines’ integrated development and manufacturing capabilities, as well as its world-class quality system, to enhance the OMV Plus platform. OMV Plus, launched in 2023, addresses key technical challenges in traditional OMV design and production through advanced pathogen genome editing technology. This platform enables the production of OMV, natural nanovesicles released by Gram-negative bacteria, which carry a large amount of bacterial antigens, including proteins and polysaccharides.
Market and Public Health Impact
OMV technology is recognized as a promising next-generation approach for bacterial vaccines, offering solutions to the complexities of antigen screening and development. The engineered OMV platform is commercially validated and offers the advantage of inherent adjuvant properties due to its rich content of pathogen-associated molecular patterns (PAMPs), enhancing vaccine efficacy without additional adjuvants. This collaboration positions Delonix and WuXi Vaccines at the forefront of innovation in bacterial vaccine development, contributing to global public health initiatives.-Fineline Info & Tech